Skip to main content
PMC home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1995 Jul;2(4):462–468. doi: 10.1128/cdli.2.4.462-468.1995

Interlaboratory variability of CD8 subset measurements by flow cytometry and its applications to multicenter clinical trials. NAID/NICHD Women and Infants Transmission Study Group.

A L Landay 1, D Brambilla 1, J Pitt 1, G Hillyer 1, D Golenbock 1, J Moye 1, S Landesman 1, J Kagan 1
PMCID: PMC170180  PMID: 7583925

Abstract

Recent studies have demonstrated the utility of measuring subsets of CD8+ T cells as prognostic markers in epidemiology cohort studies of human immunodeficiency virus (HIV)-infected patients. Most of these studies evaluating the value of CD8+ T-cell subsets have been performed at single centers, and few data are available on variability in the measurement of the CD8+ cell populations in multicenter trials. In the current study, we addressed this question by evaluating interlaboratory variability from the five laboratories enrolled in the Women and Infants Transmission Study sponsored by the National Institutes of Health. This study evaluated 35 HIV-positive and 28 HIV-negative proficiency testing samples sent to the laboratories for evaluation. The study focused on the robust coefficient of variation (RCV) for CD38 (11%), HLA-DR (21%), and CD57 (15%) expression on the CD8+ population. Data from the current study indicated that the variability in these measurements is greater than that for CD3+ CD4+ (RCV, 5%) and CD3+ CD8+ (RCV, 5%) cells. Knowledge of the variability of the CD8+ subset measurements should guide investigators in the design and analysis of clinical trials and epidemiology studies. Ability to obtain improved interlaboratory agreement on CD8+ subset measurements will facilitate further evaluation of these markers in HIV studies.

Full Text

The Full Text of this article is available as a PDF (201.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aranda-Anzaldo A. A role for CD8+ T lymphocytes in the pathogenesis of AIDS. Res Immunol. 1991 Sep;142(7):541–550. doi: 10.1016/0923-2494(91)90099-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ariyoshi K., Harwood E., Chiengsong-Popov R., Weber J. Is clearance of HIV-1 viraemia at seroconversion mediated by neutralising antibodies? Lancet. 1992 Nov 21;340(8830):1257–1258. doi: 10.1016/0140-6736(92)92953-d. [DOI] [PubMed] [Google Scholar]
  3. Bland J. M., Altman D. G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986 Feb 8;1(8476):307–310. [PubMed] [Google Scholar]
  4. Bofill M., Janossy G., Lee C. A., MacDonald-Burns D., Phillips A. N., Sabin C., Timms A., Johnson M. A., Kernoff P. B. Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol. 1992 May;88(2):243–252. doi: 10.1111/j.1365-2249.1992.tb03068.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Borrow P., Lewicki H., Hahn B. H., Shaw G. M., Oldstone M. B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994 Sep;68(9):6103–6110. doi: 10.1128/jvi.68.9.6103-6110.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Calvelli T., Denny T. N., Paxton H., Gelman R., Kagan J. Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry. 1993 Oct;14(7):702–715. doi: 10.1002/cyto.990140703. [DOI] [PubMed] [Google Scholar]
  7. Carmichael A., Jin X., Sissons P., Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med. 1993 Feb 1;177(2):249–256. doi: 10.1084/jem.177.2.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cheingsong-Popov R., Panagiotidi C., Bowcock S., Aronstam A., Wadsworth J., Weber J. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. BMJ. 1991 Jan 5;302(6767):23–26. doi: 10.1136/bmj.302.6767.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fahley J. L. Doing it right: measuring T cell subsets by flow cytometry. Clin Immunol Immunopathol. 1990 May;55(2):171–172. doi: 10.1016/0090-1229(90)90095-8. [DOI] [PubMed] [Google Scholar]
  10. Gelman R., Cheng S. C., Kidd P., Waxdal M., Kagan J. Assessment of the effects of instrumentation, monoclonal antibody, and fluorochrome on flow cytometric immunophenotyping: a report based on 2 years of the NIAID DAIDS flow cytometry quality assessment program. Clin Immunol Immunopathol. 1993 Feb;66(2):150–162. doi: 10.1006/clin.1993.1019. [DOI] [PubMed] [Google Scholar]
  11. Gelman R., Eudey L. Biostatistical considerations for quality assessment of immunologic measurements used in clinical and longitudinal studies. Clin Immunol Immunopathol. 1989 Jul;52(1):28–37. doi: 10.1016/0090-1229(89)90190-6. [DOI] [PubMed] [Google Scholar]
  12. Giorgi J. V., Cheng H. L., Margolick J. B., Bauer K. D., Ferbas J., Waxdal M., Schmid I., Hultin L. E., Jackson A. L., Park L. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Group. Clin Immunol Immunopathol. 1990 May;55(2):173–186. doi: 10.1016/0090-1229(90)90096-9. [DOI] [PubMed] [Google Scholar]
  13. Giorgi J. V., Detels R. T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin Immunol Immunopathol. 1989 Jul;52(1):10–18. doi: 10.1016/0090-1229(89)90188-8. [DOI] [PubMed] [Google Scholar]
  14. Giorgi J. V., Ho H. N., Hirji K., Chou C. C., Hultin L. E., O'Rourke S., Park L., Margolick J. B., Ferbas J., Phair J. P. CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group. J Infect Dis. 1994 Oct;170(4):775–781. doi: 10.1093/infdis/170.4.775. [DOI] [PubMed] [Google Scholar]
  15. Ho H. N., Hultin L. E., Mitsuyasu R. T., Matud J. L., Hausner M. A., Bockstoce D., Chou C. C., O'Rourke S., Taylor J. M., Giorgi J. V. Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol. 1993 Apr 1;150(7):3070–3079. [PubMed] [Google Scholar]
  16. Hoffenbach A., Langlade-Demoyen P., Dadaglio G., Vilmer E., Michel F., Mayaud C., Autran B., Plata F. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J Immunol. 1989 Jan 15;142(2):452–462. [PubMed] [Google Scholar]
  17. Kestens L., Vanham G., Gigase P., Young G., Hannet I., Vanlangendonck F., Hulstaert F., Bach B. A. Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection. AIDS. 1992 Aug;6(8):793–797. doi: 10.1097/00002030-199208000-00004. [DOI] [PubMed] [Google Scholar]
  18. Klatzmann D., Barré-Sinoussi F., Nugeyre M. T., Danquet C., Vilmer E., Griscelli C., Brun-Veziret F., Rouzioux C., Gluckman J. C., Chermann J. C. Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science. 1984 Jul 6;225(4657):59–63. doi: 10.1126/science.6328660. [DOI] [PubMed] [Google Scholar]
  19. Kristiansen S. A statistical procedure for the estimation of accuracy parameters in interlaboratory studies. Stat Med. 1991 Jun;10(6):843–854. doi: 10.1002/sim.4780100607. [DOI] [PubMed] [Google Scholar]
  20. Landay A. L., Mackewicz C. E., Levy J. A. An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol. 1993 Oct;69(1):106–116. doi: 10.1006/clin.1993.1157. [DOI] [PubMed] [Google Scholar]
  21. Levacher M., Hulstaert F., Tallet S., Ullery S., Pocidalo J. J., Bach B. A. The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. Clin Exp Immunol. 1992 Dec;90(3):376–382. doi: 10.1111/j.1365-2249.1992.tb05854.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mackewicz C. E., Ortega H. W., Levy J. A. CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest. 1991 Apr;87(4):1462–1466. doi: 10.1172/JCI115153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mihailov C., Lamour A., Beaudré-Bellein V., Jézequel N., Garré M., Mottier D., Guillet G., Youinou P. Prognostic significance of cytotoxic T cells in individuals infected with human immunodeficiency virus. J Clin Immunol. 1993 Mar;13(2):139–144. doi: 10.1007/BF00919270. [DOI] [PubMed] [Google Scholar]
  24. Pantaleo G., Koenig S., Baseler M., Lane H. C., Fauci A. S. Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+CD8+DR+CD25- T cell population. J Immunol. 1990 Mar 1;144(5):1696–1704. [PubMed] [Google Scholar]
  25. Parker J. W., Adelsberg B., Azen S. P., Boone D., Fletcher M. A., Gjerset G. F., Hassett J., Kaplan J., Niland J. C., Odom-Maryon T. Leukocyte immunophenotyping by flow cytometry in a multisite study: standardization, quality control, and normal values in the Transfusion Safety Study. The Transfusion Safety Study Group. Clin Immunol Immunopathol. 1990 May;55(2):187–220. doi: 10.1016/0090-1229(90)90097-a. [DOI] [PubMed] [Google Scholar]
  26. Paxton H., Kidd P., Landay A., Giorgi J., Flomenberg N., Walker E., Valentine F., Fahey J., Gelman R. Results of the flow cytometry ACTG quality control program: analysis and findings. Clin Immunol Immunopathol. 1989 Jul;52(1):68–84. doi: 10.1016/0090-1229(89)90194-3. [DOI] [PubMed] [Google Scholar]
  27. Piatak M., Jr, Saag M. S., Yang L. C., Clark S. J., Kappes J. C., Luk K. C., Hahn B. H., Shaw G. M., Lifson J. D. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 1993 Mar 19;259(5102):1749–1754. doi: 10.1126/science.8096089. [DOI] [PubMed] [Google Scholar]
  28. Plata F., Autran B., Martins L. P., Wain-Hobson S., Raphaël M., Mayaud C., Denis M., Guillon J. M., Debré P. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature. 1987 Jul 23;328(6128):348–351. doi: 10.1038/328348a0. [DOI] [PubMed] [Google Scholar]
  29. Prince H. E., Jensen E. R. Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection. J Acquir Immune Defic Syndr. 1991;4(12):1227–1232. [PubMed] [Google Scholar]
  30. Rickman W. J., Monical C., Waxdal M. J. Improved precision in the enumeration of absolute numbers of lymphocyte phenotypes with long-term monthly proficiency testing. Ann N Y Acad Sci. 1993 Mar 20;677:53–58. doi: 10.1111/j.1749-6632.1993.tb38764.x. [DOI] [PubMed] [Google Scholar]
  31. Rickman W. J., Waxdal M. J., Monical C., Damato J. D., Burke D. S. Department of Army lymphocyte immunophenotyping quality assurance program. Clin Immunol Immunopathol. 1989 Jul;52(1):85–95. doi: 10.1016/0090-1229(89)90195-5. [DOI] [PubMed] [Google Scholar]
  32. Sadat-Sowti B., Debré P., Idziorek T., Guillon J. M., Hadida F., Okzenhendler E., Katlama C., Mayaud C., Autran B. A lectin-binding soluble factor released by CD8+CD57+ lymphocytes from AIDS patients inhibits T cell cytotoxicity. Eur J Immunol. 1991 Mar;21(3):737–741. doi: 10.1002/eji.1830210329. [DOI] [PubMed] [Google Scholar]
  33. Schenker E. L., Hultin L. E., Bauer K. D., Ferbas J., Margolick J. B., Giorgi J. V. Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. Cytometry. 1993;14(3):307–317. doi: 10.1002/cyto.990140311. [DOI] [PubMed] [Google Scholar]
  34. Vanham G., Kestens L., Penne G., Goilav C., Gigase P., Colebunders R., Vandenbruaene M., Goeman J., van der Groen G., Ceuppens J. L. Subset markers of CD8(+) cells and their relation to enhanced cytotoxic T-cell activity during human immunodeficiency virus infection. J Clin Immunol. 1991 Nov;11(6):345–356. doi: 10.1007/BF00918800. [DOI] [PubMed] [Google Scholar]
  35. Walker B. D., Chakrabarti S., Moss B., Paradis T. J., Flynn T., Durno A. G., Blumberg R. S., Kaplan J. C., Hirsch M. S., Schooley R. T. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature. 1987 Jul 23;328(6128):345–348. doi: 10.1038/328345a0. [DOI] [PubMed] [Google Scholar]
  36. Walker C. M., Erickson A. L., Hsueh F. C., Levy J. A. Inhibition of human immunodeficiency virus replication in acutely infected CD4+ cells by CD8+ cells involves a noncytotoxic mechanism. J Virol. 1991 Nov;65(11):5921–5927. doi: 10.1128/jvi.65.11.5921-5927.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Walker C. M., Moody D. J., Stites D. P., Levy J. A. CD8+ T lymphocyte control of HIV replication in cultured CD4+ cells varies among infected individuals. Cell Immunol. 1989 Apr 1;119(2):470–475. doi: 10.1016/0008-8749(89)90259-1. [DOI] [PubMed] [Google Scholar]
  38. Walker C. M., Moody D. J., Stites D. P., Levy J. A. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science. 1986 Dec 19;234(4783):1563–1566. doi: 10.1126/science.2431484. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES